CommercialCoverageLow impact
08.01.89a, Betibeglogene Autotemcel [Beti-Cel (ZYNTEGLO®)]
Independence Blue Cross·Hematology, Oncology·Pharmacy
Effective date
May 28, 2025
We identified it
Jun 19, 2026
Summary
This is a commercial insurance policy update for Betibeglogene Autotemcel (Beti-Cel/ZYNTEGLO), a gene therapy treatment. The policy has been reissued and will take effect on May 28, 2025.
Action Required
By May 28, 2025: Billing team should review the updated policy for Betibeglogene Autotemcel (ZYNTEGLO) gene therapy at the provided URL to understand any coverage or prior authorization changes. This affects a very rare specialized treatment, so immediate action is not critical unless your practice provides gene therapy services.